Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.35 USD
Change Today -0.05 / -2.08%
Volume 924.8K
CRIS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

curis inc (CRIS) Snapshot

Open
$2.40
Previous Close
$2.40
Day High
$2.40
Day Low
$2.26
52 Week High
02/17/15 - $3.50
52 Week Low
12/18/14 - $1.09
Market Cap
261.1M
Average Volume 10 Days
931.0K
EPS TTM
$-0.21
Shares Outstanding
111.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CURIS INC (CRIS)

curis inc (CRIS) Related Businessweek News

No Related Businessweek News Found

curis inc (CRIS) Details

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase I clinical trials for advanced lymphomas and multiple myeloma; and HER 2-/ ER+ or PR+ breast cancer, and NUT midline carcinoma. It also develops CUDC-427 that is in Phase I clinical trials for advanced solid tumor and lymphomas; programmed death ligand-1 antagonist, which is in preclinical stage for the treatment of cancers; small molecule Interleukin-1 receptor-associated kinase 4 inhibitor that is in preclinical stage for the treatment of hematological cancers; and CUDC-305 drug candidate, which is in trials in patients with systemic mastocytosis and glioblastoma multiforme for the treatment of cancers. In addition, the company offers Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma (BCC). Its Erivedge is also in Phase II clinical trials for preceding excision and/or multiple BCC, and idiopathic pulmonary fibrosis. The company has collaboration agreement with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and collaboration and license agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

35 Employees
Last Reported Date: 02/24/15
Founded in 2000

curis inc (CRIS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $366.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $360.0K
Vice Chairman and Strategic Advisor
Total Annual Compensation: $464.9K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $142.8K
Vice President of Technology Management & Int...
Total Annual Compensation: $230.0K
Compensation as of Fiscal Year 2013.

curis inc (CRIS) Key Developments

Curis Seeks Acquisitions

Curis, Inc. (NasdaqGM:CRIS) priced its common stock offering resulting in aggregate proceeds of $60 million. Curis will use the proceeds to fund potential acquisitions of new business, technologies or products that it believes complement or expand its business, and for general working capital and capital expenditures.

Curis, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Curis, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, revenues were $1,992,699 against $1,524,137 for the same period a year ago. Net loss from operations was $4,811,088 against $4,483,217 for the same period a year ago. Net loss was $5,688,870 or $0.07 basic and diluted per share against net loss of $4,198,032 or $0.05 basic and diluted per share for the same period a year ago. For the year, revenues were $9,843,481 against $15,002,032 for the same period a year ago. Net loss from operations was $15,862,249 against $9,416,409 for the same period a year ago. Net loss was $18,728,734 or $0.22 basic and diluted per share against $12,322,012 or $0.15 basic and diluted per share for the same period a year ago. The decrease in revenues for the year ended December 31, 2014 was primarily due to a decrease in license fee revenues from Genentech of $7 million when compared to the year ending 2013.

Curis Seeks Acquisitions

Curis, Inc. (NasdaqGM:CRIS) is seeking acquisitions. Curis has filed to sell common stock. The net proceeds from its offering may be used to fund potential acquisitions of new business.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRIS:US $2.35 USD -0.05

CRIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $2.25 USD +0.01
CTI BioPharma Corp $1.83 USD +0.02
Cytokinetics Inc $7.00 USD +0.22
MELA Sciences Inc $2.48 USD -0.09
Navidea Biopharmaceuticals Inc $1.59 USD 0.00
View Industry Companies
 

Industry Analysis

CRIS

Industry Average

Valuation CRIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.0x
Price/Book 6.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CURIS INC, please visit www.curis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.